[
  {
    "inputSequence": {
      "header": "unk",
      "SHA512": "413a7aa6619f1656ad4bdee1f385cb228f698613f24781ae4ef21dc7afe4b6972b62ff6f0a1f97edd0118d0af73bfedce084c47a1bdc484616ea59c2214e528a"
    },
    "subtypeText": "B (3.60%)",
    "validationResults": [
      {
        "level": "WARNING",
        "message": "The RT sequence had 5 amino acids trimmed from its 5\u2032-end due to poor quality."
      }
    ],
    "alignedGeneSequences": [
      {
        "firstAA": 35,
        "lastAA": 247,
        "gene": {
          "name": "RT",
          "length": 560
        },
        "mutations": [
          {
            "consensus": "V",
            "position": 35,
            "AAs": "L",
            "isInsertion": false,
            "isDeletion": false,
            "isApobecDRM": false
          },
          {
            "consensus": "E",
            "position": 36,
            "AAs": "N",
            "isInsertion": false,
            "isDeletion": false,
            "isApobecDRM": false
          },
          {
            "consensus": "I",
            "position": 37,
            "AAs": "F",
            "isInsertion": false,
            "isDeletion": false,
            "isApobecDRM": false
          },
          {
            "consensus": "R",
            "position": 83,
            "AAs": "K",
            "isInsertion": false,
            "isDeletion": false,
            "isApobecDRM": false
          },
          {
            "consensus": "V",
            "position": 90,
            "AAs": "IV",
            "isInsertion": false,
            "isDeletion": false,
            "isApobecDRM": false
          },
          {
            "consensus": "K",
            "position": 101,
            "AAs": "PQ",
            "isInsertion": false,
            "isDeletion": false,
            "isApobecDRM": false
          },
          {
            "consensus": "D",
            "position": 123,
            "AAs": "E",
            "isInsertion": false,
            "isDeletion": false,
            "isApobecDRM": false
          },
          {
            "consensus": "S",
            "position": 163,
            "AAs": "T",
            "isInsertion": false,
            "isDeletion": false,
            "isApobecDRM": false
          },
          {
            "consensus": "P",
            "position": 176,
            "AAs": "PT",
            "isInsertion": false,
            "isDeletion": false,
            "isApobecDRM": false
          },
          {
            "consensus": "D",
            "position": 177,
            "AAs": "DE",
            "isInsertion": false,
            "isDeletion": false,
            "isApobecDRM": false
          },
          {
            "consensus": "I",
            "position": 178,
            "AAs": "IM",
            "isInsertion": false,
            "isDeletion": false,
            "isApobecDRM": false
          },
          {
            "consensus": "Y",
            "position": 181,
            "AAs": "CY",
            "isInsertion": false,
            "isDeletion": false,
            "isApobecDRM": false
          },
          {
            "consensus": "M",
            "position": 184,
            "AAs": "V",
            "isInsertion": false,
            "isDeletion": false,
            "isApobecDRM": false
          },
          {
            "consensus": "G",
            "position": 190,
            "AAs": "AG",
            "isInsertion": false,
            "isDeletion": false,
            "isApobecDRM": false
          },
          {
            "consensus": "T",
            "position": 200,
            "AAs": "AT",
            "isInsertion": false,
            "isDeletion": false,
            "isApobecDRM": false
          },
          {
            "consensus": "R",
            "position": 211,
            "AAs": "KR",
            "isInsertion": false,
            "isDeletion": false,
            "isApobecDRM": false
          },
          {
            "consensus": "V",
            "position": 245,
            "AAs": "E",
            "isInsertion": false,
            "isDeletion": false,
            "isApobecDRM": false
          }
        ],
        "SDRMs": [
          {
            "text": "K101P"
          },
          {
            "text": "Y181C"
          },
          {
            "text": "M184V"
          },
          {
            "text": "G190A"
          }
        ],
        "alignedNAs": "TTAAATTTTTGTACAGAAATGGAAAAGGAAGGGAAAATTTCAAAAATTGGGCCTGAAAACCCATACAATACTCCAGTATTTGCCATAAAGAAAAAAGACAGTACTAAATGGAGAAAATTAGTAGATTTTAGAGAACTTAATAAGAAAACTCAAGACTTCTGGGAARTTCAATTAGGAATACCACATCCCGCAGGGTTACMGAAGAAAAAATCAGTAACAGTACTRGATGTGGGTGATGCATATTTTTCAGTTCCCTTAGATAAAGAATTCAGGAAGTATACTGCATTYACCATACCTAGTATAAACAATGAGACACCAGGRATTAGRTATCAGTACAATGTGCTGCCACAGGGATGGAAAGGGTCACCAGCAATATTCCAAAGTACCATGACAAAAATYTTAGAACCTTTTAGAAAACAAAATMCAGAMATRGTTATTTRTCAGTACGTGGATGATTTGTATGTAGSATCTGACTTAGAAATAGGGCAGCATAGARCAAAAATAGAGGAACTGAGACAGCATYTATTGARGTGGGGRTTTACCACACCAGACAAAAAGCATCAGAAAGAACCTCCATTYCTGTGGATGGGTTATGAACTCCATCCTGATAAGTGGACAGTACAGCCTATAGAGTTGCCA",
        "alignedAAs": "LNFCTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKKTQDFWEIQLGIPHPAGLXKKKSVTVLDVGDAYFSVPLDKEFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSTMTKILEPFRKQNTEMVICQYVDDLYVASDLEIGQHRAKIEELRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELP",
        "prettyPairwise": {
          "positionLine": [
            "35 ",
            "36 ",
            "37 ",
            "38 ",
            "39 ",
            "40 ",
            "41 ",
            "42 ",
            "43 ",
            "44 ",
            "45 ",
            "46 ",
            "47 ",
            "48 ",
            "49 ",
            "50 ",
            "51 ",
            "52 ",
            "53 ",
            "54 ",
            "55 ",
            "56 ",
            "57 ",
            "58 ",
            "59 ",
            "60 ",
            "61 ",
            "62 ",
            "63 ",
            "64 ",
            "65 ",
            "66 ",
            "67 ",
            "68 ",
            "69 ",
            "70 ",
            "71 ",
            "72 ",
            "73 ",
            "74 ",
            "75 ",
            "76 ",
            "77 ",
            "78 ",
            "79 ",
            "80 ",
            "81 ",
            "82 ",
            "83 ",
            "84 ",
            "85 ",
            "86 ",
            "87 ",
            "88 ",
            "89 ",
            "90 ",
            "91 ",
            "92 ",
            "93 ",
            "94 ",
            "95 ",
            "96 ",
            "97 ",
            "98 ",
            "99 ",
            "100",
            "101",
            "102",
            "103",
            "104",
            "105",
            "106",
            "107",
            "108",
            "109",
            "110",
            "111",
            "112",
            "113",
            "114",
            "115",
            "116",
            "117",
            "118",
            "119",
            "120",
            "121",
            "122",
            "123",
            "124",
            "125",
            "126",
            "127",
            "128",
            "129",
            "130",
            "131",
            "132",
            "133",
            "134",
            "135",
            "136",
            "137",
            "138",
            "139",
            "140",
            "141",
            "142",
            "143",
            "144",
            "145",
            "146",
            "147",
            "148",
            "149",
            "150",
            "151",
            "152",
            "153",
            "154",
            "155",
            "156",
            "157",
            "158",
            "159",
            "160",
            "161",
            "162",
            "163",
            "164",
            "165",
            "166",
            "167",
            "168",
            "169",
            "170",
            "171",
            "172",
            "173",
            "174",
            "175",
            "176",
            "177",
            "178",
            "179",
            "180",
            "181",
            "182",
            "183",
            "184",
            "185",
            "186",
            "187",
            "188",
            "189",
            "190",
            "191",
            "192",
            "193",
            "194",
            "195",
            "196",
            "197",
            "198",
            "199",
            "200",
            "201",
            "202",
            "203",
            "204",
            "205",
            "206",
            "207",
            "208",
            "209",
            "210",
            "211",
            "212",
            "213",
            "214",
            "215",
            "216",
            "217",
            "218",
            "219",
            "220",
            "221",
            "222",
            "223",
            "224",
            "225",
            "226",
            "227",
            "228",
            "229",
            "230",
            "231",
            "232",
            "233",
            "234",
            "235",
            "236",
            "237",
            "238",
            "239",
            "240",
            "241",
            "242",
            "243",
            "244",
            "245",
            "246",
            "247"
          ],
          "refAALine": [
            " V ",
            " E ",
            " I ",
            " C ",
            " T ",
            " E ",
            " M ",
            " E ",
            " K ",
            " E ",
            " G ",
            " K ",
            " I ",
            " S ",
            " K ",
            " I ",
            " G ",
            " P ",
            " E ",
            " N ",
            " P ",
            " Y ",
            " N ",
            " T ",
            " P ",
            " V ",
            " F ",
            " A ",
            " I ",
            " K ",
            " K ",
            " K ",
            " D ",
            " S ",
            " T ",
            " K ",
            " W ",
            " R ",
            " K ",
            " L ",
            " V ",
            " D ",
            " F ",
            " R ",
            " E ",
            " L ",
            " N ",
            " K ",
            " R ",
            " T ",
            " Q ",
            " D ",
            " F ",
            " W ",
            " E ",
            " V ",
            " Q ",
            " L ",
            " G ",
            " I ",
            " P ",
            " H ",
            " P ",
            " A ",
            " G ",
            " L ",
            " K ",
            " K ",
            " K ",
            " K ",
            " S ",
            " V ",
            " T ",
            " V ",
            " L ",
            " D ",
            " V ",
            " G ",
            " D ",
            " A ",
            " Y ",
            " F ",
            " S ",
            " V ",
            " P ",
            " L ",
            " D ",
            " K ",
            " D ",
            " F ",
            " R ",
            " K ",
            " Y ",
            " T ",
            " A ",
            " F ",
            " T ",
            " I ",
            " P ",
            " S ",
            " I ",
            " N ",
            " N ",
            " E ",
            " T ",
            " P ",
            " G ",
            " I ",
            " R ",
            " Y ",
            " Q ",
            " Y ",
            " N ",
            " V ",
            " L ",
            " P ",
            " Q ",
            " G ",
            " W ",
            " K ",
            " G ",
            " S ",
            " P ",
            " A ",
            " I ",
            " F ",
            " Q ",
            " S ",
            " S ",
            " M ",
            " T ",
            " K ",
            " I ",
            " L ",
            " E ",
            " P ",
            " F ",
            " R ",
            " K ",
            " Q ",
            " N ",
            " P ",
            " D ",
            " I ",
            " V ",
            " I ",
            " Y ",
            " Q ",
            " Y ",
            " M ",
            " D ",
            " D ",
            " L ",
            " Y ",
            " V ",
            " G ",
            " S ",
            " D ",
            " L ",
            " E ",
            " I ",
            " G ",
            " Q ",
            " H ",
            " R ",
            " T ",
            " K ",
            " I ",
            " E ",
            " E ",
            " L ",
            " R ",
            " Q ",
            " H ",
            " L ",
            " L ",
            " R ",
            " W ",
            " G ",
            " F ",
            " T ",
            " T ",
            " P ",
            " D ",
            " K ",
            " K ",
            " H ",
            " Q ",
            " K ",
            " E ",
            " P ",
            " P ",
            " F ",
            " L ",
            " W ",
            " M ",
            " G ",
            " Y ",
            " E ",
            " L ",
            " H ",
            " P ",
            " D ",
            " K ",
            " W ",
            " T ",
            " V ",
            " Q ",
            " P ",
            " I ",
            " V ",
            " L ",
            " P "
          ],
          "alignedNAsLine": [
            "TTA",
            "AAT",
            "TTT",
            "TGT",
            "ACA",
            "GAA",
            "ATG",
            "GAA",
            "AAG",
            "GAA",
            "GGG",
            "AAA",
            "ATT",
            "TCA",
            "AAA",
            "ATT",
            "GGG",
            "CCT",
            "GAA",
            "AAC",
            "CCA",
            "TAC",
            "AAT",
            "ACT",
            "CCA",
            "GTA",
            "TTT",
            "GCC",
            "ATA",
            "AAG",
            "AAA",
            "AAA",
            "GAC",
            "AGT",
            "ACT",
            "AAA",
            "TGG",
            "AGA",
            "AAA",
            "TTA",
            "GTA",
            "GAT",
            "TTT",
            "AGA",
            "GAA",
            "CTT",
            "AAT",
            "AAG",
            "AAA",
            "ACT",
            "CAA",
            "GAC",
            "TTC",
            "TGG",
            "GAA",
            "RTT",
            "CAA",
            "TTA",
            "GGA",
            "ATA",
            "CCA",
            "CAT",
            "CCC",
            "GCA",
            "GGG",
            "TTA",
            "CMG",
            "AAG",
            "AAA",
            "AAA",
            "TCA",
            "GTA",
            "ACA",
            "GTA",
            "CTR",
            "GAT",
            "GTG",
            "GGT",
            "GAT",
            "GCA",
            "TAT",
            "TTT",
            "TCA",
            "GTT",
            "CCC",
            "TTA",
            "GAT",
            "AAA",
            "GAA",
            "TTC",
            "AGG",
            "AAG",
            "TAT",
            "ACT",
            "GCA",
            "TTY",
            "ACC",
            "ATA",
            "CCT",
            "AGT",
            "ATA",
            "AAC",
            "AAT",
            "GAG",
            "ACA",
            "CCA",
            "GGR",
            "ATT",
            "AGR",
            "TAT",
            "CAG",
            "TAC",
            "AAT",
            "GTG",
            "CTG",
            "CCA",
            "CAG",
            "GGA",
            "TGG",
            "AAA",
            "GGG",
            "TCA",
            "CCA",
            "GCA",
            "ATA",
            "TTC",
            "CAA",
            "AGT",
            "ACC",
            "ATG",
            "ACA",
            "AAA",
            "ATY",
            "TTA",
            "GAA",
            "CCT",
            "TTT",
            "AGA",
            "AAA",
            "CAA",
            "AAT",
            "MCA",
            "GAM",
            "ATR",
            "GTT",
            "ATT",
            "TRT",
            "CAG",
            "TAC",
            "GTG",
            "GAT",
            "GAT",
            "TTG",
            "TAT",
            "GTA",
            "GSA",
            "TCT",
            "GAC",
            "TTA",
            "GAA",
            "ATA",
            "GGG",
            "CAG",
            "CAT",
            "AGA",
            "RCA",
            "AAA",
            "ATA",
            "GAG",
            "GAA",
            "CTG",
            "AGA",
            "CAG",
            "CAT",
            "YTA",
            "TTG",
            "ARG",
            "TGG",
            "GGR",
            "TTT",
            "ACC",
            "ACA",
            "CCA",
            "GAC",
            "AAA",
            "AAG",
            "CAT",
            "CAG",
            "AAA",
            "GAA",
            "CCT",
            "CCA",
            "TTY",
            "CTG",
            "TGG",
            "ATG",
            "GGT",
            "TAT",
            "GAA",
            "CTC",
            "CAT",
            "CCT",
            "GAT",
            "AAG",
            "TGG",
            "ACA",
            "GTA",
            "CAG",
            "CCT",
            "ATA",
            "GAG",
            "TTG",
            "CCA"
          ],
          "mutationLine": [
            " L ",
            " N ",
            " F ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " K ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            "VI ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            "PQ ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " E ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " T ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            "PT ",
            "DE ",
            "IM ",
            " - ",
            " - ",
            "YC ",
            " - ",
            " - ",
            " V ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            "GA ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            "TA ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            "RK ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " E ",
            " - ",
            " - "
          ]
        }
      }
    ],
    "drugResistance": [
      {
        "version": {
          "text": "8.8",
          "publishDate": "2019-02-13"
        },
        "gene": {
          "name": "RT"
        },
        "drugScores": [
          {
            "drugClass": {
              "name": "NRTI"
            },
            "drug": {
              "name": "ABC",
              "displayAbbr": "ABC"
            },
            "score": 15.0,
            "partialScores": [
              {
                "mutations": [
                  {
                    "text": "M184V",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
                      }
                    ]
                  }
                ],
                "score": 15.0
              }
            ],
            "text": "Low-Level Resistance"
          },
          {
            "drugClass": {
              "name": "NRTI"
            },
            "drug": {
              "name": "AZT",
              "displayAbbr": "AZT"
            },
            "score": -10.0,
            "partialScores": [
              {
                "mutations": [
                  {
                    "text": "M184V",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
                      }
                    ]
                  }
                ],
                "score": -10.0
              }
            ],
            "text": "Susceptible"
          },
          {
            "drugClass": {
              "name": "NRTI"
            },
            "drug": {
              "name": "D4T",
              "displayAbbr": "D4T"
            },
            "score": -10.0,
            "partialScores": [
              {
                "mutations": [
                  {
                    "text": "M184V",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
                      }
                    ]
                  }
                ],
                "score": -10.0
              }
            ],
            "text": "Susceptible"
          },
          {
            "drugClass": {
              "name": "NRTI"
            },
            "drug": {
              "name": "DDI",
              "displayAbbr": "DDI"
            },
            "score": 10.0,
            "partialScores": [
              {
                "mutations": [
                  {
                    "text": "M184V",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
                      }
                    ]
                  }
                ],
                "score": 10.0
              }
            ],
            "text": "Potential Low-Level Resistance"
          },
          {
            "drugClass": {
              "name": "NRTI"
            },
            "drug": {
              "name": "FTC",
              "displayAbbr": "FTC"
            },
            "score": 60.0,
            "partialScores": [
              {
                "mutations": [
                  {
                    "text": "M184V",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
                      }
                    ]
                  }
                ],
                "score": 60.0
              }
            ],
            "text": "High-Level Resistance"
          },
          {
            "drugClass": {
              "name": "NRTI"
            },
            "drug": {
              "name": "LMV",
              "displayAbbr": "3TC"
            },
            "score": 60.0,
            "partialScores": [
              {
                "mutations": [
                  {
                    "text": "M184V",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
                      }
                    ]
                  }
                ],
                "score": 60.0
              }
            ],
            "text": "High-Level Resistance"
          },
          {
            "drugClass": {
              "name": "NRTI"
            },
            "drug": {
              "name": "TDF",
              "displayAbbr": "TDF"
            },
            "score": -10.0,
            "partialScores": [
              {
                "mutations": [
                  {
                    "text": "M184V",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
                      }
                    ]
                  }
                ],
                "score": -10.0
              }
            ],
            "text": "Susceptible"
          },
          {
            "drugClass": {
              "name": "NNRTI"
            },
            "drug": {
              "name": "DOR",
              "displayAbbr": "DOR"
            },
            "score": 40.0,
            "partialScores": [
              {
                "mutations": [
                  {
                    "text": "K101P",
                    "primaryType": "NNRTI",
                    "comments": [
                      {
                        "type": "NNRTI",
                        "text": "K101P is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Its does not appear to reduce DOR susceptibility."
                      }
                    ]
                  }
                ],
                "score": 10.0
              },
              {
                "mutations": [
                  {
                    "text": "Y181C",
                    "primaryType": "NNRTI",
                    "comments": [
                      {
                        "type": "NNRTI",
                        "text": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
                      }
                    ]
                  }
                ],
                "score": 10.0
              },
              {
                "mutations": [
                  {
                    "text": "Y181C",
                    "primaryType": "NNRTI",
                    "comments": [
                      {
                        "type": "NNRTI",
                        "text": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
                      }
                    ]
                  },
                  {
                    "text": "G190A",
                    "primaryType": "NNRTI",
                    "comments": [
                      {
                        "type": "NNRTI",
                        "text": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
                      }
                    ]
                  }
                ],
                "score": 20.0
              }
            ],
            "text": "Intermediate Resistance"
          },
          {
            "drugClass": {
              "name": "NNRTI"
            },
            "drug": {
              "name": "EFV",
              "displayAbbr": "EFV"
            },
            "score": 135.0,
            "partialScores": [
              {
                "mutations": [
                  {
                    "text": "K101P",
                    "primaryType": "NNRTI",
                    "comments": [
                      {
                        "type": "NNRTI",
                        "text": "K101P is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Its does not appear to reduce DOR susceptibility."
                      }
                    ]
                  }
                ],
                "score": 60.0
              },
              {
                "mutations": [
                  {
                    "text": "Y181C",
                    "primaryType": "NNRTI",
                    "comments": [
                      {
                        "type": "NNRTI",
                        "text": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
                      }
                    ]
                  }
                ],
                "score": 30.0
              },
              {
                "mutations": [
                  {
                    "text": "G190A",
                    "primaryType": "NNRTI",
                    "comments": [
                      {
                        "type": "NNRTI",
                        "text": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
                      }
                    ]
                  }
                ],
                "score": 45.0
              }
            ],
            "text": "High-Level Resistance"
          },
          {
            "drugClass": {
              "name": "NNRTI"
            },
            "drug": {
              "name": "ETR",
              "displayAbbr": "ETR"
            },
            "score": 110.0,
            "partialScores": [
              {
                "mutations": [
                  {
                    "text": "K101P",
                    "primaryType": "NNRTI",
                    "comments": [
                      {
                        "type": "NNRTI",
                        "text": "K101P is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Its does not appear to reduce DOR susceptibility."
                      }
                    ]
                  }
                ],
                "score": 60.0
              },
              {
                "mutations": [
                  {
                    "text": "Y181C",
                    "primaryType": "NNRTI",
                    "comments": [
                      {
                        "type": "NNRTI",
                        "text": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
                      }
                    ]
                  }
                ],
                "score": 30.0
              },
              {
                "mutations": [
                  {
                    "text": "G190A",
                    "primaryType": "NNRTI",
                    "comments": [
                      {
                        "type": "NNRTI",
                        "text": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
                      }
                    ]
                  }
                ],
                "score": 10.0
              },
              {
                "mutations": [
                  {
                    "text": "Y181C",
                    "primaryType": "NNRTI",
                    "comments": [
                      {
                        "type": "NNRTI",
                        "text": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
                      }
                    ]
                  },
                  {
                    "text": "G190A",
                    "primaryType": "NNRTI",
                    "comments": [
                      {
                        "type": "NNRTI",
                        "text": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
                      }
                    ]
                  }
                ],
                "score": 10.0
              }
            ],
            "text": "High-Level Resistance"
          },
          {
            "drugClass": {
              "name": "NNRTI"
            },
            "drug": {
              "name": "NVP",
              "displayAbbr": "NVP"
            },
            "score": 180.0,
            "partialScores": [
              {
                "mutations": [
                  {
                    "text": "K101P",
                    "primaryType": "NNRTI",
                    "comments": [
                      {
                        "type": "NNRTI",
                        "text": "K101P is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Its does not appear to reduce DOR susceptibility."
                      }
                    ]
                  }
                ],
                "score": 60.0
              },
              {
                "mutations": [
                  {
                    "text": "Y181C",
                    "primaryType": "NNRTI",
                    "comments": [
                      {
                        "type": "NNRTI",
                        "text": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
                      }
                    ]
                  }
                ],
                "score": 60.0
              },
              {
                "mutations": [
                  {
                    "text": "G190A",
                    "primaryType": "NNRTI",
                    "comments": [
                      {
                        "type": "NNRTI",
                        "text": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
                      }
                    ]
                  }
                ],
                "score": 60.0
              }
            ],
            "text": "High-Level Resistance"
          },
          {
            "drugClass": {
              "name": "NNRTI"
            },
            "drug": {
              "name": "RPV",
              "displayAbbr": "RPV"
            },
            "score": 130.0,
            "partialScores": [
              {
                "mutations": [
                  {
                    "text": "K101P",
                    "primaryType": "NNRTI",
                    "comments": [
                      {
                        "type": "NNRTI",
                        "text": "K101P is a non-polymorphic mutation that causes high-level resistance to each of the NNRTIs. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Its does not appear to reduce DOR susceptibility."
                      }
                    ]
                  }
                ],
                "score": 60.0
              },
              {
                "mutations": [
                  {
                    "text": "Y181C",
                    "primaryType": "NNRTI",
                    "comments": [
                      {
                        "type": "NNRTI",
                        "text": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
                      }
                    ]
                  }
                ],
                "score": 45.0
              },
              {
                "mutations": [
                  {
                    "text": "G190A",
                    "primaryType": "NNRTI",
                    "comments": [
                      {
                        "type": "NNRTI",
                        "text": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
                      }
                    ]
                  }
                ],
                "score": 15.0
              },
              {
                "mutations": [
                  {
                    "text": "Y181C",
                    "primaryType": "NNRTI",
                    "comments": [
                      {
                        "type": "NNRTI",
                        "text": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
                      }
                    ]
                  },
                  {
                    "text": "G190A",
                    "primaryType": "NNRTI",
                    "comments": [
                      {
                        "type": "NNRTI",
                        "text": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
                      }
                    ]
                  }
                ],
                "score": 10.0
              }
            ],
            "text": "High-Level Resistance"
          }
        ]
      }
    ]
  }
]